Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of Multiple Myeloma~* Patients intended to be treated with myeloablative therapy and autologous hematopoetic stem-cell transplant within one month of stem-cell collection~* Patients whose stem-cell mobilization regimen includes G-CSF (granulocyte-colony stimulating factor)~* Males or non-pregnant females, who are 18 years of age or older~* Karnofsky score of ≥70%~Exclusion Criteria:~* Patients with pre-mobilization platelet count \< 75,000/µL~* Patients who have received pelvic bone marrow irradiation as part of their conditioning therapy~* Patients who have had a previous hematopoetic stem-cell transplant~* Patients who have had a previous hematopoetic stem-cell collection failure~* Impaired cardiac function, as evidenced by left ventricular ejection fraction \<40%.~* Impaired hepatic function, as evidenced by alanine transaminase \>2.5 x normal~* Impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon monoxide (adjusted for patient hematocrit, if indicated) or forced expiratory volume in 1 second \<50% of predicted~* Impaired renal function, as evidenced by a creatinine clearance \< 40 mL/min~* Impaired coagulation, as evidenced by a prothrombin time (PT) \> twice normal~* Pregnancy or lactation~* Seropositivity for Human Immunodeficiency Virus-1/2, Hepatitis B Virus, or Hepatitis C Virus~* Documented bacterial or fungal infection that requires intravenous antibiotics to be started or continued while undergoing apheresis collection on the Spectra Optia device~* Subjects enrolled in study protocols that could affect number of CD34+ cells (pluripoten hematopoetic stem stells) collected or kinetics of neutrophil recovery~* Altered mental status, as evidenced by the inability to provide effective informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with multiple myeloma (Type: EXPERIMENTAL): Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.

Based on this trial design, predict the completion outcome and termination type (if applicable).